Wed, October 11, 2017
Tue, October 10, 2017
Mon, October 9, 2017
Fri, October 6, 2017
Thu, October 5, 2017
Wed, October 4, 2017
Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017
Thu, September 28, 2017
Wed, September 27, 2017
Tue, September 26, 2017
Mon, September 25, 2017
Fri, September 22, 2017
Thu, September 21, 2017
Wed, September 20, 2017
Tue, September 19, 2017
Mon, September 18, 2017

Terence Flynn Upgraded (ALNY) to Strong Buy on, Oct 2nd, 2017


//stocks-investing.news-articles.net/content/201 .. upgraded-alny-to-strong-buy-on-oct-2nd-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Terence Flynn of Goldman Sachs, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Strong Buy on, Oct 2nd, 2017.

Terence has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 2 agree with Terence's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $101 on, Thursday, September 21st, 2017


These are the ratings of the 5 analyists that currently disagree with Terence


  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $134 on, Friday, September 22nd, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $127 on, Thursday, September 21st, 2017
  • Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $123 on, Thursday, September 21st, 2017
  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017

Publication Contributing Sources